Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Alpharadin

- PMLiVE

Bayer pins hopes on five potential blockbusters

Riociguat, alpharadin, Stivarga, Eylea, and Xarelto expected to reach sales of €5.5bn by 2015

- PMLiVE

Second approval in US for Bayer-Onyx’ Stivarga

FDA clears drug to treat patients with gastrointestinal stromal tumours

- PMLiVE

Actavis sales rise but profits slump as Lipitor effect recedes

Reports first set of results since merger with Watson

- PMLiVE

Shire weathers generic Adderall XR challenge

Fourth quarter revenues rise 5 per cent to $1.1bn

- PMLiVE

FDA fast-tracks Bayer’s prostate cancer radiotherapy

Priority review for radium-223 dichloride, formerly called Alpharadin

- PMLiVE

Bayer submits oral PAH drug riociguat for approval

Set to challenge Actelion and Gilead

- PMLiVE

Lundbeck looks to new products as Lexapro slumps

Denmark-based pharma company reports flat sales during fourth quarter of 2012

EU flag

Pharma backs new European drug discovery platform

Supporters for the European Lead Factory include Bayer AstraZeneca, Merck KGaA and Sanofi

Sanofi reception

Sanofi predicts end of patent cliff in 2013

New launches to overcome generic competition

- PMLiVE

GSK planning restructuring in Europe as earnings fall

Includes job cuts and potential sale of Ribena/Lucozade brands

- PMLiVE

Sanofi receives EU approvals for diabetes and cancer drugs

Zaltrap and Lyxumia granted marketing authorisation by European Commission

- PMLiVE

Merck & Co shares fall on Q4 results, osteoporosis drug delay

Sales down on loss of patent protection for Singulair

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links